ID
37273
Beschrijving
Study ID: 104864/902 Clinical Study ID: 104864/902 Study Title: An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00316173 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: CARBOPLATIN Study Indication: Ovarian Cancer; Neoplasms, Ovarian
Trefwoorden
Versies (1)
- 12-07-19 12-07-19 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
12 juli 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
HYCAMTIN in Combination With Carboplatin in Subjects with Ovarian Cancer; NCT00316173
Investigational Product Discontinuation
- StudyEvent: ODM
Beschrijving
Investigational Product Discontinuation
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0457454
Beschrijving
Experimental drug, Discontinued, Reason and justification
Datatype
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1444662
- UMLS CUI [1,3]
- C0566251
Beschrijving
Experimental drug, Discontinued, Reason and justification
Datatype
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1444662
- UMLS CUI [1,3]
- C0566251
Similar models
Investigational Product Discontinuation
- StudyEvent: ODM
C0457454 (UMLS CUI-2)
C1444662 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])
C1444662 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])